MabGenesis Inc. is a biopharmaceutical startup based in Japan, established on June 3, 2019. The company specializes in the research and development of therapeutic monoclonal antibody drugs intended for both humans and companion animals, utilizing advanced technologies and a proprietary antibody library. MabGenesis leverages over 30 years of academic research in antibody development, employing its MOURA Library and IMPACT technology to create species-specific antibodies targeting complex diseases. Headquartered in Yokohama, Kanagawa, MabGenesis has engaged in notable partnerships, including a collaborative agreement with Boehringer Ingelheim in January 2022 for the development of monoclonal antibody therapeutics for dogs. By June 2025, the company filed a patent for a novel antibody, achieving a significant milestone with Kyoritsu Seiyaku Corporation. Additionally, in April 2026, MabGenesis was highlighted in the Nikkei, focusing on its advancements in antibody therapeutics. The leadership team comprises experienced professionals from the pharmaceutical and biotechnology sectors, including Katsuhiro Shinjo (CEO), Shinichi Koizumi (Director), Ryu Maeda (CSO), Yuichiro Shibazaki (CBO), and Gene Kurosawa (CTO), each carrying extensive backgrounds in major pharmaceutical companies and research institutions. As of March 2023, MabGenesis had a workforce of approximately 10 individuals. Currently, there is no public information suggesting that the company has filed for or completed an Initial Public Offering (IPO).
AI-researched from public web sources — may contain errors or omissions and is not a substitute for verifying independently.
MabGenesis Inc. is expected to list on JPX. The expected date is Nov 2, 2026. MabGenesis Inc. is headquartered in Japan. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with MabGenesis Inc..
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/mabgenesis" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="MabGenesis Inc. — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/mabgenesis?theme=light as the src instead.
https://www.discoveripo.com/ipo/mabgenesis/opengraph-image
MabGenesis Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/mabgenesis?utm_source=embed&utm_medium=text&utm_campaign=mabgenesis
Get emailed when MabGenesis Inc.'s terms, price, or expected date change — no weekly noise, just this company.
MabGenesis Inc. is expected to list on Nov 2, 2026.
MabGenesis Inc. is listing on JPX.
MabGenesis Inc. is a biopharmaceutical startup based in Japan, established on June 3, 2019. The company specializes in the research and development of therapeutic monoclonal antibody drugs intended for both humans and companion animals, utilizing advanced technologies and a proprietary antibody library. MabGenesis leverages over 30 years of academic research in antibody development, employing its MOURA Library and IMPACT technology to create species-specific antibodies targeting complex diseases. Headquartered in Yokohama, Kanagawa, MabGenesis has engaged in notable partnerships, including a collaborative agreement with Boehringer Ingelheim in January 2022 for the development of monoclonal antibody therapeutics for dogs. By June 2025, the company filed a patent for a novel antibody, achieving a significant milestone with Kyoritsu Seiyaku Corporation. Additionally, in April 2026, MabGenesis was highlighted in the Nikkei, focusing on its advancements in antibody therapeutics. The leadership team comprises experienced professionals from the pharmaceutical and biotechnology sectors, including Katsuhiro Shinjo (CEO), Shinichi Koizumi (Director), Ryu Maeda (CSO), Yuichiro Shibazaki (CBO), and Gene Kurosawa (CTO), each carrying extensive backgrounds in major pharmaceutical companies and research institutions. As of March 2023, MabGenesis had a workforce of approximately 10 individuals. Currently, there is no public information suggesting that the company has filed for or completed an Initial Public Offering (IPO).
Japan Financial Services Agency's EDINET disclosure system — a securities registration filing date, not a confirmed listing date. Retrieved Sep 28, 2026.
View the original filing on EDINET →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy